CHGCY Chugai Pharmaceutical Co Unsp/Adrs
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, marketing, and distribution of prescription medicines in Japan and internationally. The company's products for oncology primarily include Avastin, Herceptin, Rituxan, Alecensa, Perjeta, Xeloda, Tarceva, Kadcyla, Zelboraf, Neutrogin, Tecentriq, and Gazyva; bone and joint diseases/autoimmune diseases comprise Actemra, Edirol, Suvenyl, and Bonviva; renal diseases consist of Mircera and Oxarol; and other diseases comprise Tamiflu, CellCept, Copegus, and Hemlibra. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group and Genentech; and co-development agreements with Taisho Pharmaceutical Co., Ltd. and Nippon Shinyaku Co., Ltd. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd. This is an ADR of a company whose stock trades outside of the U.S. as the symbol JT:4519.
This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.
$12.37 Pink
As of 03/23/2023 OTCMarkets
Security Information
Category1: US Equity
Category2: ADRs
Category3: Large cap
GICS sector: Health Care
Industry: Drug Manufacturers-General
Index country: Japan
Country of incorporation: Japan
IPO date: 11/21/2018
Outstanding shares: 3,358,115,334
Average volume: 121,276
Market cap: $41,539,886,682
Current dividend yield: 0.00%
All SEC filings: SEC Edgar Online
Quarterly filings: 10-Q
Annual filings: 10-K
Sedol:
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%